Ziv-aflibercept in XXXX .

@entity1 @entity32 @entity2194 @entity137 @entity6027 @entity6 @entity231 @entity5 @entity7 @entity989 @entity1020
BACKGROUND/AIMS: Aflibercept is an approved therapy for neovascular @entity1020 ( @entity1020 ) and @entity6 ( @entity6 ). In vitro and in vivo studies did not detect @entity137 to the retinal pigment epithelium cells using the approved @entity5 protein, ziv-aflibercept. Our purpose is to determine if ziv-aflibercept can be used in @entity1020 and @entity6 without @entity2194 , to test the stability of ziv-aflibercept, and to do a cost analysis. METHODS: Prospectively, consecutive @entity1 with @entity1020 or @entity6 and poor vision underwent one intravitreal injection of 0.05   mL of fresh filtered ziv-aflibercept (1.25   mg). Monitoring of best-corrected visual acuity, @entity32 , @entity231 progression, and retinal structure by spectral domain optical coherence tomography was done at 1   day and 1   week after injection. Ziv-aflibercept activity over 4   weeks was measured by capturing @entity7 by ELISA. RESULTS: There were no signs of @entity989 , @entity32 or change in lens status in four eyes with @entity1020 and two eyes with @entity6 . Visual acuity improved (p=0.05) and central foveal thickness decreased in all @entity1 (p=0.05). Ziv-aflibercept had no loss of anti- @entity7 activity when kept at 4  C in @entity6027 syringes over 4   weeks. Similar to bevacizumab, compounded ziv-aflibercept would yield a tremendous saving compared with aflibercept or ranibizumab. CONCLUSIONS: Off-label use of ziv-aflibercept improves visual acuity without @entity2194 and may offer a cheaper alternative to the same molecule aflibercept. TRIAL REGISTRATION NUMBER: NCT02173873.
